Multimodal tumor suppression by METTL3 gene knockdown in melanoma and colon cancer cells

Arezoo Bazargani1, Masoumeh Fakhr Taha1, Bahram Mohammad Soltani2

  • 1Department of Stem Cells and Regenerative Medicine, Institute for Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Blvd., P.O. Box 14965-161, Tehran, Iran.

PubMed

Insights

Inhibiting METTL3 (methyltransferase-like 3) significantly reduced proliferation and invasion in colorectal and melanoma cancer cells. This suggests METTL3 plays a pro-oncogenic role, making it a potential target for cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • METTL3 is a key methyltransferase regulating mRNA modifications (N6-methyladenosine).
  • Dysregulation of m6A homeostasis is linked to cancer development, progression, and metastasis.
  • METTL3's specific role in colorectal and melanoma cancer requires further elucidation.

Purpose of the Study:

  • To investigate the functional impact of METTL3 knockdown on colorectal and melanoma cancer cell lines.
  • To assess the effects of METTL3 inhibition on cancer cell proliferation, invasion, migration, and apoptosis.

Main Methods:

  • Short hairpin RNA (shRNA) was used to knockdown METTL3 in SW480 (colorectal) and A375 (melanoma) cell lines.
  • Quantitative PCR (qPCR) analyzed gene expression changes.
  • Three-dimensional (3D) spheroid invasion assays assessed invasive capabilities.
  • Cell cycle and apoptosis analyses were performed.

Main Results:

  • METTL3 knockdown significantly downregulated key genes (VIM, SNAI1, SNAI2, ZEB1, CDH1, TGFB1) and proteins (beta-catenin, N-cadherin, vimentin, MMP2, OCT4A, SOX2, MYC).
  • Proliferation rates decreased, while apoptosis rates increased in METTL3-silenced cells.
  • Cancer cell migration and invasion were significantly reduced following METTL3 knockdown.

Conclusions:

  • METTL3 exhibits a pro-oncogenic function in colorectal and melanoma cancer cells.
  • Inhibiting METTL3 demonstrates potential as a therapeutic strategy for tumor suppression.
  • Further research is warranted to validate these findings for broader cancer applications.